Abstract
Objective To discuss the influence of high-dose recombinant human growth hormone (rhGH) therapy on serum vitamin D and insulin-like growth factor-1 (IGF-1) levels in school-age children with idiopathic short stature (ISS). Method A total of 103 school-age children with ISS were selected from June 2016 to June 2020 in our hospital. The enrolled cases were divided into the low-dose group (n = 59) and high-dose group (n = 44) according to the treatment dose of rhGH. After the treatment, the height (Ht), height standard deviation score (Ht SDS), growth velocity (GV), and other indicators were recorded. The serum 25-hydroxy vitamin D [25-(OH)D] and IGF-1 levels of the two groups were tested, and the occurrence of adverse reactions was recorded. Results After treatment, the high-dose group outperformed the low-dose group in various growth effect indicators such as Ht, Ht SDS, and GV (P < 0.05). After treatment, the serum 25-(OH)D of children with ISS in the two groups increased significantly, but there was no significant difference between the two groups (P > 0.05). After treatment, the serum IGF-1 of children with ISS in the two groups increased significantly, but there was no significant difference between the two groups (P > 0.05). For children with ISS, adverse reactions induced by rhGH therapy were very rare. There was no significant difference in the incidence of adverse reactions induced by different doses of rhGH in the treatment of ISS (P > 0.05). Conclusion rhGH has definite efficacy in the treatment of ISS children, for it can significantly increase the annual growth rate of ISS children in a dose-dependent manner. High-dose rhGH for ISS has a better therapeutic effect. At the same time, regardless of the dose level of rhGH, serum 25-(OH)D and IGF-1 levels in children with ISS were increased, with less adverse reactions and higher safety.
Highlights
Childhood short stature is a growth and development disorder with a high prevalence
The high-dose group outperformed the low-dose group in various growth effect indicators such as Ht, height standard deviation score (Ht SDS), and growth velocity (GV) (P < 0.05)
For children with idiopathic short stature (ISS), adverse reactions induced by recombinant human growth hormone (rhGH) therapy were very rare. ere was no significant difference in the incidence of adverse reactions induced by different doses of rhGH in the treatment of ISS (P > 0.05)
Summary
Childhood short stature is a growth and development disorder with a high prevalence. The research results released by the WHO in 2000 showed that the prevalence of short stature had a great correlation with the degree of national economic development. Idiopathic short stature (ISS) is the most common type of short stature, accounting for 60%– 80% of children with short stature [3]. ISS refers to that the height of the child is lower than that of the child of the same age and gender by two standard deviations, the general height and weight at birth are normal, and there is no evidence to support systemic, endocrine, nutritional, and chromosomal abnormalities. If children have short stature, it is easy to cause children’s life, behavior, and psychological disorders. Erefore, effective treatment for school-age children with ISS is urgently needed Children are often frustrated for various reasons, which leads to children lagging behind their peers in Evidence-Based Complementary and Alternative Medicine social interaction, leading to different degrees of psychological problems [5]. erefore, effective treatment for school-age children with ISS is urgently needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
